BIVOLUTX: Bicuspid Aortic Stenosis With Evolut Platform International Experience.

NCT03495050 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2018-06-12

No results posted yet for this study

Summary

Prospective non interventional, observational registry of 150 patients undergoing TAVI with Evolut platform for bicuspid aortic stenosis.

Conditions

  • Bicuspid Aortic Valve

Interventions

DEVICE

Transcatheter Aortic Valve Implantation

Transcatheter treatment of bicuspid aortic stenosis with the Evolut Pro/XL platform

Sponsors & Collaborators

  • Clinique Pasteur

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-21
Primary Completion
2019-05-31
Completion
2020-05-31
FDA Device
Yes

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03495050 on ClinicalTrials.gov